Cancer Research Aziza Shad  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 1408-1411, April 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Couch, F. J.
Right arrow Articles by James, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Couch, F. J.
Right arrow Articles by James, C. D.
[Cancer Research 59, 1408-1411, April 1, 1999]
© 1999 American Association for Cancer Research


Advances in Brief

Localization of PS6K to Chromosomal Region 17q23 and Determination of Its Amplification in Breast Cancer1

Fergus J. Couch, Xiao-Yang Wang, Guo-Jun Wu, Junqi Qian, Robert B. Jenkins and C. David James2

Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905


    ABSTRACT
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The application of comparative genomic hybridization to the analysis of genetic abnormalities in breast carcinoma has consistently revealed that chromosome region 17q22–24 is a frequent site of gene amplification in this type of cancer. As part of an examination of expressed sequence tags for novel amplified genes in this region, we identified PS6K amplifications in both breast tumor tissues and cell lines. PS6K was localized to 17q23 and encodes a serine-threonine kinase whose activation is thought to regulate a wide array of cellular processes involved in the mitogenic response including protein synthesis, translation of specific mRNA species, and cell cycle progression from G1 to S phase. Northern and Western analyses revealed that amplification of this gene was accompanied by corresponding increases in mRNA and protein expression, respectively. These data represent the first determination of a gene amplification within 17q22–24 in breast cancer and suggest an oncogenic activity for PS6K.


    Introduction
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Gene amplification is a common event in breast cancer, and it has been shown to involve multiple loci at various chromosomal locations. Of these, the long arm of chromosome 17 is the most frequently affected, and it contains independently amplified regions at q21 (1 , 2) and q22–24 (3, 4, 5) . ERBB2 is located at 17q21 and is well accepted as the target gene for amplifications within this region, although additional amplified sequences have been identified at this chromosomal location (6) . Specific genes involved in q22–24 amplifications have yet to be identified, and until recently, these alterations had only been demonstrated by comparative genomic hybridization (3 , 4) , a technique with limited resolving power.

There are, however, several approaches that one may take to the identification of amplified genes once a cytogenetic location has been established for an amplicon of interest. One that we have recently used (7) involves the utilization of databases containing regionally localized ESTs.3 By synthesizing ESTs and applying them as probes to the Southern analysis of appropriate tumor DNAs, it is possible to identify amplified genes as well as to construct amplicon maps. By using this approach for the analysis of the 17q22–24 region in breast cancer, we have identified two amplified and overexpressed sequences. One of the ESTs is associated with a known gene, PS6K. In mammalian cells, the protein product of PS6K, s6k, is thought to activate the translation initiation machinery in response to growth factor stimulation of its upstream regulator, TOR (8) , and s6k activity has been shown to be necessary for entry into S phase of the cell cycle (9 , 10) . In combination with these functional properties of s6k, our genetic data suggest an oncogenic activity for PS6K and indicate the existence of additional chromosome 17q amplification targets.


    Materials and Methods
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Tumor Tissues and Cell Lines.
All tumors used in this study were obtained from patients undergoing surgical treatment at the Mayo Clinic (Rochester, MN) and were diagnosed as primary stage 2 breast carcinomas. The breast carcinoma cell lines examined, MDA-157, UACC-893, MCF-7, BT-474, UACC-812, and MDA-361, were obtained from American Type Culture Collection.

Nucleic Acid Extraction and Analysis.
Cell line and tumor DNAs were isolated as described previously (11) . DNAs were treated with HindIII restriction enzyme, electrophoresed through 0.8% agarose gels, transferred to a reinforced nitrocellulose membrane (Nytran; Schleicher and Schuell, Keene, NH), and fixed to the membrane by baking in a vacuum oven at 80°C for 2 h.

RNA extractions from cell lines were performed with a modification of the technique described by Chomczynski and Sacchi (12) , in which pelleted cells were lysed in a guanidinium isothiocyanate-phenol solution (Trizol; Life Technologies, Inc.) by vortexing. After the addition of one-fifth volume of chloroform to sample lysates, specimens were vortexed again and centrifuged. Aqueous, RNA-containing phases were isolated from centrifuged specimens, and sample RNAs were precipitated with isopropanol and resuspended in DEPC-treated H2O. RNA samples were electrophoresed through formaldehyde-agarose gels (1.0%) and blot-transferred and fixed to nitrocellulose membranes as described above.

DNA and RNA filters were hybridized with 32P-labeled probes for PS6K (cDNA bases 1520–1695, synthesized by PCR of genomic DNA) and ERBB2 (full-length cDNA coding sequence, bases 149-3955). After hybridization, filters were washed and exposed to X-ray film; treatments of DNA and RNA filters for multiple, sequential hybridizations have been described previously (11 , 13) .

Protein Isolation and Western Analysis.
Breast tumor cell line pellets were swelled in cold PBS at room temperature for 15 min and lysed by repeated passage through a 27-gauge needle. Lysates were cleared of insoluble material by microcentrifugation at 13,000 rpm for 15 min at 4°C, and protein concentrations were determined (protein assay kit; Bio-Rad). Approximately 50 µg of total protein from each sample were boiled in loading buffer for 5 min, electrophoresed through 10% polyacrylamide gels, and electroblotted to a reinforced nitrocellulose membrane (Hybond-C extra; Amersham). The membrane was incubated overnight at 4°C in a blocking solution consisting of 0.1% Tween 20, 1x Tris-buffered saline, and 5% nonfat dry milk. Incubation with primary antibody (rabbit antihuman s6k: Santa Cruz Biotechnology) was performed for 2 h at room temperature in blocking solution. After incubation with primary antibody, filters were washed repeatedly in PBS with 0.1% Tween 20 at room temperature and then incubated in blocking solution for 1 h at room temperature with horseradish peroxidase-labeled secondary antibody (goat antirabbit IgG; BMB). Signal detection of filter-bound secondary antibody was by horseradish peroxidase chemiluminescent reaction (ECL; Amersham).

FISH Analysis.
Hybridizations of a SpectrumGreen-labeled chromosome 17 centromeric probe (Vysis, Downers Grove, IL) and a SpectrumOrange-labeled PS6K probe (isolated from the RPCI-11 Human BAC Library; Research Genetics) were performed on slides containing either normal or MCF-7 metaphase chromosomes. Metaphase chromosomes were prepared for hybridization by heating at 65°C for 1 h followed by a 37°C incubation in 2x SSC for 1 h followed by a 1 min incubation in 70% formamide at 72°C. Chromosome 17 centromere and PS6K probes that had been heated at 74°C for 5 min were applied to the denatured metaphase chromosomes and incubated at 37°C overnight. Posthybridization washes were performed in 0.4x SSC at 72°C for 3 min, followed by 4x SSC-0.1% Tween 20 for 5 min at room temperature and then 5 min in 2x SSC at room temperature. Hybridization signals were detected using a Zeiss Axioplan microscope equipped with a triple-pass filter (4',6-diamidino-2-phenylindole/Green/Orange: Vysis).


    Results
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Cell lines previously determined to have one or more regions of 17q amplification (5) were examined by Southern analysis using several EST probes localized to the q22–24 region (Table 1)Citation . Two of these, WI-6034 and WI-6857, showed normalized dosage increases of >4-fold in three of the cell lines (MCF-7, BT-474, and MDA-361; Fig. 1ACitation ). When the same filter was rehybridized with an ERBB2 probe, increased signal response was evident in BT-474 and MDA-361 but not in MCF-7 DNA.


View this table:
[in this window]
[in a new window]

 
Table 1 EST amplification patterns in breast tumor cell lines

 


View larger version (60K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 1. Determination of PS6K amplification and overexpression. A, DNAs from the indicated cell lines and from a normal tissue control were digested with HindIII restriction enzyme, electrophoresed through a 0.8% agarose gel, and blot-transferred to a nylon membrane. The membrane was successively hybridized with the indicated probes and the autoradiograms associated with each hybridization are shown. B, total cell line RNAs were electrophoresed through a 1.0% formaldehyde-agarose gel, blot-transferred to a reinforced nitrocellulose filter, and hybridized with the indicated probes. C, total cell line proteins were electrophoresed through an 8% polyacrylamide gel and blot-transferred to a nitrocellulose membrane. The membrane was incubated with anti-s6k antibody, followed by incubation with horseradish peroxidase-labeled secondary antibody. Detection of bound secondary antibody was by chemiluminescent reaction of the horseradish peroxidase. D, tumor DNAs were analyzed for amplification of the PS6K EST WI-6034 as described in A. *, tumor in which PS6K is amplified independently of ERBB2.

 
The WI-6034 EST was determined to be part of the PS6K gene, and the use of this EST as a probe for Northern analysis revealed two transcripts (Fig. 1B)Citation , results consistent with previously published data on PS6K expression (14) . As was the case for WI-6034, hybridization of WI-6857 revealed overexpressed transcripts (data not shown) in the cell lines in which it is amplified. This latter EST is not associated with a known gene. Expression levels for the protein product of PS6K, s6k, were detected in cell lines by Western blot analysis. The results showed predominant expression of the p70 isoform (14 , 15) and, as would be expected based upon the Southern analysis, s6k expression was highly elevated in cell lines with PS6K amplification (Fig. 1C)Citation .

To determine whether PS6K amplification occurs in primary tumors, we examined 14 breast carcinoma DNAs for increased dosage of the WI-6034 EST (Fig. 1D)Citation . Amplified PS6K was evident in two of these cases, and in one instance, it was apparent that its amplification occurred without the amplification of ERBB2. Elevated s6k expression was also evident in tumors with amplified PS6K (data not shown).

To confirm the genomic location of PS6K, we performed FISH analysis on normal metaphase chromosomes using a BAC clone identified from the RPCI-11 Human BAC Library using primers for the WI-6034 EST. Surprisingly, two regions of 17q homology were revealed by this analysis: one near the centromere and a second more distal in the expected q22–24 region (Fig. 2A)Citation . Comparison of FISH signal locations against corresponding G-banded chromosome images showed that the distal signal was located in band q23. Simultaneous hybridization of ERBB2 and PS6K probes revealed that the ERBB2 gene was located between the two signals associated with the PS6K probe and was, in fact, much nearer to the centromere-proximal PS6K homology region (data not shown). Hybridization of the PS6K BAC to MCF-7 cells also failed to provide a definitive chromosomal location of the PS6K amplicon as amplified regions were observed on several rearranged marker chromosomes (Fig. 2B)Citation .



View larger version (109K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 2. FISH analysis of metaphase chromosomes from normal and MCF-7 breast tumor cells. Arrows (top), dual signals from the q arm of each chromosome 17. Bottom, PS6K amplification regions are evident on several marker chromosomes in MCF7 cells.

 
To determine which of the 17q locations contained PS6K, we collected two additional pieces of data. The first of these was obtained from the Stanford radiation hybrid G3 mapping panel, which was used for localizing WI-6034. The results from this analysis clearly positioned the EST within the distal 17q region based upon its centiRay map location (2517 cR, estimated distance from p-ter = 61.4 Mb) and orientation relative to ERBB2 (1460 cR, estimated distance from p-ter = 45.5 Mb). In addition, WI-6034 has been localized to the 17.8 17q23 yeast artificial chromosome contig, generated and sequenced at the Whitehead Institute. The deduced PS6K exon-intron structure from this contig sequence is shown in Fig. 3Citation and reveals 15 exons extending over ~50 kb of genomic DNA. Collectively, these data indicate that the PS6K amplicon should reside within q23, and this location is consistent with the 17q amplification region assigned to MCF7 cells by comparative genomic hybridization analysis (5) .



View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Genomic (top) and cDNA (bottom) structure of PS6K as determined from the analysis of chromosome 17 sequence entered into the Whitehead Institute database. Exon sizes (in bp) were as follows: 1, 162; 2, 50; 3, 122; 4, 71; 5, 150; 6, 58; 7, 103; 8, 93; 9, 90; 10, 107; 11, 67; 12, 77; 13, 109; 14, 121; 15, 977. *, alternative translation initiation sites (15) for the two isoforms of s6k (Mr 70,000 and 85,000 forms).

 

    Discussion
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
In this study, we used a panel of mapped EST markers to examine a region of chromosome 17q for novel gene amplifications. This analysis led to the identification of two amplified and overexpressed sequences, one of which is associated with a gene encoding a protein that functions to promote cell proliferation (8) . Because of its proximity to ERBB2, it is reasonable to question whether PS6K is only amplified as a result of its being a "bystander" to a well-documented oncogene; this appears to be the case for DDX1, which resides within a region that can be coamplified with MYCN in neuroblastoma (16 , 17) . We have shown, however, that PS6K amplification can occur independently of ERBB2, thereby establishing a circumstance similar to that observed for the independent or coamplifications of CDK4 and MDM2 that occur in chromosomal region 12q13–15 (18 , 19) .

Despite its established role in the mitogenic response, it is far from clear whether PS6K represents a target gene for 17q amplifications in breast cancer. The results of this study only provide a starting place from which to begin a comprehensive analysis of the amplification region. Ultimately, the determination of amplification targets in 17q22–24 will rely on a combination of amplicon mapping and functional analyses of amplified genes.

An interesting aspect of this study concerns the identification of a duplicated region on 17q (Fig. 2A)Citation . Our examination of DNA sequence flanking the PS6K gene (BAC hRPK178_C_3) resulted in the identification of loci having >80% homology with the TRE-2 and TRE-17 genes, both of which have been localized to a centromere-proximal region on 17 (20) . The amount of DNA encompassing these two genes is at least 60 kb, supporting the idea that a large segment of 17q has been duplicated. It is interesting to speculate that these duplicated regions may play a role in mediating the amplifications as well as deletions of 17q that occur in a large proportion of breast tumors; further analysis of these regions should provide some insight regarding this possibility.


    FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported in part by a grant from the Breast Cancer Research Foundation. Back

2 To whom requests for reprints should be addressed, at Mayo Clinic and Foundation, 200 First Street, SW, Hilton Building, Room 820-D, Rochester, MN 55905. Phone: (507) 284-8989; Fax: (507) 266-5193; E-mail: james.charles{at}mayo.edu Back

3 The abbreviations used are: EST, expressed sequence tag; FISH, fluorescence in situ hybridization; BAC, bacterial artificial chromosome. Back

Received 1/ 7/99. Accepted 2/16/99.


    REFERENCES
 Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Fukushige S., Matsubara K., Yoshida M., Sasaki M., Suzuki T., Semba K., Toyoshima K., Yamamoto T. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome17 and its amplification in a gastric cancer cell line. Mol. Cell. Biol., 6: 955-958, 1986.[Abstract/Free Full Text]
  2. Muleris M., Almeida A., Malfoy B., Dutrillaux B. Assignment of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) to human chromosome band 17q21.1 by in situ hybridization. Cytogenet. Cell Genet., 76: 34-35, 1997.[Medline]
  3. Muleris M., Almeida A., Gerbault-Seureau M., Malfoy B., Dutrillaux B. Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions. Genes Chromosomes Cancer, 14: 155-163, 1995.[Medline]
  4. Courjal F., Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res., 57: 4368-4377, 1977.[Abstract/Free Full Text]
  5. Barlund M., Tirkkonen M., Forozan F., Tanner M. M., Kallioniemi O., Kallioniemi A. Increased copy number at 17q22–q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer, 20: 372-376, 1997.[Medline]
  6. Bieche I., Tomasetto C., Regnier C. H., Moog-Lutz C., Rio M. C., Lidereau R. Two distinct amplified regions at 17q11–q21 involved in human primary breast cancer. Cancer Res., 56: 3886-3990, 1996.[Abstract/Free Full Text]
  7. Wang X. Y., Smith D. I., Frederick L., James C. D. Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene, 16: 191-195, 1998.[Medline]
  8. Brown E. J., Schreiber S. L. A signaling pathway to translational control. Cell, 86: 517-520, 1996.[Medline]
  9. Lane H. A., Fernandez A., Lamb N. J., Thomas G. p70s6k function is essential for G1 progression. Nature (Lond.), 363: 170-172, 1993.[Medline]
  10. Reinhard C., Fernandez A., Lamb N. J., Thomas G. Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J., 13: 1557-1565, 1994.[Medline]
  11. James C. D., Carlbom E., Dumanski J. P., Hansen M., Nordenskjold M., Collins V. P., Cavenee W. K. Clonal genomic alterations in glioma malignancy stages. Cancer Res., 48: 5546-5551, 1988.[Abstract/Free Full Text]
  12. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.[Medline]
  13. Ekstrand A. J., James C. D., Cavenee W. K., Seliger B., Pettersson R. F., Collins V. P. Genes for epidermal growth factor receptor, transforming growth factor {alpha}, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res., 51: 2164-2172, 1991.[Abstract/Free Full Text]
  14. Reinhard C., Thomas G., Kozma S. C. A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation. Proc. Natl. Acad. Sci. USA, 89: 4052-4056, 1992.[Abstract/Free Full Text]
  15. Grove J. R., Banerjee P., Balasubramanyam A., Coffer P. J., Price D. J., Avruch J., Woodgett J. R. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol. Cell. Biol., 11: 5541-5550, 1991.[Abstract/Free Full Text]
  16. Amler L. C., Schurmann J., Schwab M. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer, 15: 134-137, 1996.[Medline]
  17. Reiter J. L., Brodeur G. M. MYCN is the only highly expressed gene from the core amplified domain in human neuroblastomas. Genes Chromosomes Cancer, 23: 134-140, 1998.[Medline]
  18. Reifenberger G., Ichimura K., Reifenberger J., Elkahloun A. G., Meltzer P. S., Collins V. P. Refined mapping of 12q13–q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res., 56: 5141-5145, 1996.[Abstract/Free Full Text]
  19. Berner J. M., Forus A., Elkahloun A., Meltzer P. S., Fodstad O., Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer, 17: 254-259, 1996.[Medline]
  20. Onno M., Nakamura T., Hillova J., Hill M. Identification of novel sequences in the repertoire of hypervariable TRE17 genes from immortalized nonmalignant and malignant human keratinocytes. Gene, 131: 209-215, 1993.[Medline]



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. L. Yamnik, A. Digilova, D. C. Davis, Z. N. Brodt, C. J. Murphy, and M. K. Holz
S6 Kinase 1 Regulates Estrogen Receptor {alpha} in Control of Breast Cancer Cell Proliferation
J. Biol. Chem., March 6, 2009; 284(10): 6361 - 6369.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. T. Hennessy, Y. Lu, E. Poradosu, Q. Yu, S. Yu, H. Hall, M. S. Carey, M. Ravoori, A. M. Gonzalez-Angulo, R. Birch, et al.
Pharmacodynamic Markers of Perifosine Efficacy
Clin. Cancer Res., December 15, 2007; 13(24): 7421 - 7431.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Nessling, K. Richter, C. Schwaenen, P. Roerig, G. Wrobel, S. Wessendorf, B. Fritz, M. Bentz, H.-P. Sinn, B. Radlwimmer, et al.
Candidate Genes in Breast Cancer Revealed by Microarray-Based Comparative Genomic Hybridization of Archived Tissue
Cancer Res., January 15, 2005; 65(2): 439 - 447.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Koziczak and N. E. Hynes
Cooperation between Fibroblast Growth Factor Receptor-4 and ErbB2 in Regulation of Cyclin D1 Translation
J. Biol. Chem., November 26, 2004; 279(48): 50004 - 50011.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Zheng, R. Simon, M. Mirlacher, R. Maurer, T. Gasser, T. Forster, P. A. Diener, M. J. Mihatsch, G. Sauter, and P. Schraml
TRIO Amplification and Abundant mRNA Expression Is Associated with Invasive Tumor Growth and Rapid Tumor Cell Proliferation in Urinary Bladder Cancer
Am. J. Pathol., July 1, 2004; 165(1): 63 - 69.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, T. Yokoyama, S. Nozawa, J. Inazawa, and I. Imoto
Association of 17q21-q24 Gain in Ovarian Clear Cell Adenocarcinomas with Poor Prognosis and Identification of PPM1D and APPBP2 as Likely Amplification Targets
Clin. Cancer Res., June 1, 2003; 9(6): 1995 - 2004.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. J. Shah, S. Ghosh, and T. Hunter
Mitotic Regulation of Ribosomal S6 Kinase 1 Involves Ser/Thr, Pro Phosphorylation of Consensus and Non-consensus Sites by Cdc2
J. Biol. Chem., April 25, 2003; 278(18): 16433 - 16442.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
L Matyakhina, S Pack, L S Kirschner, E Pak, P Mannan, J Jaikumar, S E Taymans, F Sandrini, J A Carney, and C A Stratakis
Chromosome 2 (2p16) abnormalities in Carney complex tumours
J. Med. Genet., April 1, 2003; 40(4): 268 - 277.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. Saarela, M. Schoenberg Fejzo, D. Chen, S. Finnila, M. Parkkonen, S. Kuokkanen, E. Sobel, P. J. Tienari, M.-L. Sumelahti, J. Wikstrom, et al.
Fine mapping of a multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24
Hum. Mol. Genet., September 15, 2002; 11(19): 2257 - 2267.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. S. Sinclair, C. Adem, A. Naderi, C. L. Soderberg, M. Johnson, L. Wadum, V. L. Couch, T. A. Sellers, D. Schaid, J. Slezak, et al.
TBX2 Is Preferentially Amplified in BRCA1- and BRCA2-related Breast Tumors
Cancer Res., July 1, 2002; 62(13): 3587 - 3591.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
R Roylance
Methods of molecular analysis: assessing losses and gains in tumours
Mol. Pathol., February 1, 2002; 55(1): 25 - 28.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G.-j. Wu, C. Sinclair, S. Hinson, J. N. Ingle, P. C. Roche, and F. J. Couch
Structural Analysis of the 17q22-23 Amplicon Identifies Several Independent Targets of Amplification in Breast Cancer Cell Lines and Tumors
Cancer Res., July 1, 2001; 61(13): 4951 - 4955.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. Monni, M. Bärlund, S. Mousses, J. Kononen, G. Sauter, M. Heiskanen, P. Paavola, K. Avela, Y. Chen, M. L. Bittner, et al.
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer
PNAS, April 25, 2001; (2001) 91582298.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Bärlund, O. Monni, J. Kononen, R. Cornelison, J. Torhorst, G. Sauter, O.-P. Kallioniemi, and A. Kallioniemi
Multiple Genes at 17q23 Undergo Amplification and Overexpression in Breast Cancer
Cancer Res., October 1, 2000; 60(19): 5340 - 5344.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
G.-J. Wu, C. S. Sinclair, J. Paape, J. N. Ingle, P. C. Roche, C. D. James, and F. J. Couch
17q23 Amplifications in Breast Cancer Involve the PAT1, RAD51C, PS6K, and SIGMA1B Genes
Cancer Res., October 1, 2000; 60(19): 5371 - 5375.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
M. Barlund, F. Forozan, J. Kononen, L. Bubendorf, Y. Chen, M. L. Bittner, J. Torhorst, P. Haas, C. Bucher, G. Sauter, et al.
Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis
J Natl Cancer Inst, August 2, 2000; 92(15): 1252 - 1259.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Forozan, E. H. Mahlamäki, O. Monni, Y. Chen, R. Veldman, Y. Jiang, G. C. Gooden, S. P. Ethier, A. Kallioniemi, and O.-P. Kallioniemi
Comparative Genomic Hybridization Analysis of 38 Breast Cancer Cell Lines: A Basis for Interpreting Complementary DNA Microarray Data
Cancer Res., August 1, 2000; 60(16): 4519 - 4525.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
U. Lehmann, S. Glockner, W. Kleeberger, H. F. R. von Wasielewski, and H. Kreipe
Detection of Gene Amplification in Archival Breast Cancer Specimens by Laser-Assisted Microdissection and Quantitative Real-Time Polymerase Chain Reaction
Am. J. Pathol., June 1, 2000; 156(6): 1855 - 1864.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. Monni, M. Barlund, S. Mousses, J. Kononen, G. Sauter, M. Heiskanen, P. Paavola, K. Avela, Y. Chen, M. L. Bittner, et al.
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer
PNAS, May 8, 2001; 98(10): 5711 - 5716.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
J.-M. Rouillard, A. E. Erson, R. Kuick, J.-i. Asakawa, K. Wimmer, M. Muleris, E. M. Petty, and S. Hanash
Virtual Genome Scan: A Tool for Restriction Landmark-Based Scanning of the Human Genome
Genome Res., August 1, 2001; 11(8): 1453 - 1459.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Couch, F. J.
Right arrow Articles by James, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Couch, F. J.
Right arrow Articles by James, C. D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online